1 / 30

QSAR study on diketo acid and carboxamide derivatives as potent HIV-1 integrase inhibitor Presented By Olayide Arodola

QSAR study on diketo acid and carboxamide derivatives as potent HIV-1 integrase inhibitor Presented By Olayide Arodola (Master student – Pharmaceutical Chemistry). Aim of this study

zaynah
Download Presentation

QSAR study on diketo acid and carboxamide derivatives as potent HIV-1 integrase inhibitor Presented By Olayide Arodola

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. QSAR study on diketo acid and carboxamide derivatives as potent HIV-1 integrase inhibitor Presented By Olayide Arodola (Master student – Pharmaceutical Chemistry)

  2. Aim of this study The aim of this study is to find out how accurate the QSAR method predicted the activities of compounds in comparison to their experimental biological activities. Therefore, a 2-dimensional QSAR model was used to analyze 40 potential diketo acid and carboxamide-based compounds as HIV-1 integrase inhibitors.

  3. KEY WORDS: • Diketoacid and Carboxamide derivatives • 2D-QSAR (2-dimensional quantitative structural activity relationship) • GFA (Genetic function algorithm) • Integrase inhibitor • SOFTWARES USED IN THIS STUDY • Chemdraw ultra 10.0 (to draw 2D structures of the compounds) • Discovery studio v3.5 (to perform QSAR analysis)

  4. About HIV-1 integrase The integration of HIV-1 DNA into the host chromosome contains a series of DNA cutting and joining reactions. The first step in the integration process is 3”end processing. In the second step, termed DNA strand transfer, the viral DNA end is inserted into the target DNA. Thus, the integrase enzyme is crucial for viral replication and represents a potential target for antiretroviral drug.

  5. First, a quick reminder: what do you understand by ‘drug’ • A very broad definition of a drug would include “all chemicals other than food that affect living processes”. if it helps the body, its medicine, but if it causes a harmful effect on the body, its poison. Nowadays, we are facing a problem of screening a huge number of molecules in other to testify: • If they are toxic to human • If they have an effect on virus e.g HIV, HPV (cervical cancer), H1N1 (flu), ebolaetc

  6. Such screenings are measured by laborious experiments. • Researchers came up with a process to relate a series of molecular features with biological activities or chemical reactivities, which is expected to decrease a number of laborious and expensive experiments thereby selecting small number of good compounds for later synthesis.

  7. QSAR • QSAR is a mathematical relationship between a biological activity of a molecular system and its physical and chemical characteristics i.eQSAR represents an attempt to develop correlations between biological activity and physicochemical properties of a set of molecules. • In pharmacology, biological activity describes the beneficial or adverse effects of a drug on living matter. • Physicochemical properties of a compound simply means both its physical and chemical property. • The first application of QSAR is attributed to Hansch (1969), who developed an equation that related biological activity to certain physicochemical properties of a set of structures.

  8. WHY QSAR • The number of compounds required for synthesis in order to place 10 different groups in 4 positions of benzene ring is 104 • Solution: synthesize a small number of compounds and from their data derive rules to predict the biological activity of other compounds.

  9. Compounds + biological activity QSAR New compounds with improved biological activity QSAR and Drug Design Correlate chemical structure with activity using statistical approach

  10. BASIC PRINCIPLES A QSAR normally takes the general form of a linear equation: Biological activity = Const + (C1×P1) + (C2×P2) + (C3×P3) +... where the parameters P1 through pn are computed for each molecule in the series and the coefficients C1 through cn are calculated by fitting variations in the parameters and the biological activity. • A = k1d1 + k2d2 + k3d3 + kndn + Const A – Biological activity D – Structural properties (descriptors) K – Regression coefficient

  11. There are a series of statistical model analysis that are used to develop a QSAR model, they include: • Multiple linear regression (MLR) • Principle component analysis (PCA) • Partial least square (PLS) • Genetic function algorithm (GFA)

  12. There are a series of statistical model analysis that are used to develop a QSAR model, they include: • Multiple linear regression (MLR) • Principle component analysis (PCA) • Partial least square (PLS) • Genetic function algorithm (GFA)

  13. Why GFA • GFA was used to develop this QSAR models for variable selection. The purpose of variable selection is to select the variables significantly contributing to prediction and to discard other variables by fitness function. • Ability to build multiple models rather than single model • Ability to incorporate the lack of fit (LOF) error that resists over-fitting • Automatic removal of outliers e.g 1, 3, 6, 9, 100 • Provision of additional information not available from other statistical regression analysis

  14. Methods • Out of 40 compounds, 30 were used as a training set and 10 as a test set to evaluate the internal degree of predicitivity of the QSAR equation. • UsingChemdraw ultra 10.0, different 2D structures were drawn, followed by the conversion to 3D structures of reasonable conformations using Discovery studio v3.5 software. • A large number of descriptors were also calculated (e.g. ALogP, molecular weight, molar refractivity, dipole moment, heat of formation, Radius of gyration, Wiener index, Zagreb index etc.). • 2D QSAR analysis was carried out using genetic function algorithm (GFA) analysis.

  15. RESULT A QSAR model was generated for integrase activity. In order to select the optimal set of descriptors, we used systematic variable selection leave one out (LOO) method in a stepwise forward manner for the selection of descriptors. Three best QSAR equations models generated for this study using the GFA approach and LOO method are shown in table below.

  16. Y: pIC50, set of descriptors (W, Z, M, R, Ms,), R2: correlation coefficient, Q2: cross-validated R squared, LOF: Lack of fit, P-value: significance level

  17. pIC50 =   -11.65 − 0.0024W + 0.089Z + 0.019M + 1.187R 30 0.02 34 0.02 35 0.015 0.04 19 0.03 17

  18. Conclusion From the above result, it can be concluded that Radius of gyration, Zagreb index, Weiner index and minimized energy are statistically important with the correlation coefficient value of 0.8209, which is highly significant. This QSAR method can be used to predict the activities of future HIV-1 integrase inhibitors.

  19. References Summa, V., Petrocchi, A., Bonelli, F., Crescenzi, B., Donghi, M., Ferrara, M., Fiore, F., Gardelli, C., Paz, O. G., Hazuda, D. J., Jones, P., Kinzel, O., Laufer, R., Monteagudo, E., Muraglia, E., Nizi, E., Orvieto, F., Pace, P., Pescatore, G., Scarpelli, R., Stillmock, K., Witmer, M. V., and Rowley, M. (2008) Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection, J. Med. Chem.51, 5843-5855. Wai, J. S., Egbertson, M. S., Payne, L. S., Fisher, T. E., Embrey, M. W., Tran, L. O., Melamed, J. Y., Langford, H. M., Guare, J. P., Zhuang, L. G., Grey, V. E., Vacca, J. P., Holloway, M. K., Naylor-Olsen, A. M., Hazuda, D. J., Felock, P. J., Wolfe, A. L., Stillmock, K. A., Schleif, W. A., Gabryelski, L. J., and Young, S. D. (2000) 4-aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells, J. Med. Chem.43, 4923-4926. Wai, J. S., Kim, B., Fisher, T. E., Zhuang, L., Embrey, M. W., Williams, P. D., Staas, D. D., Culberson, C., Lyle, T. A., Vacca, J. P., Hazuda, D. J., Felock, P. J., Schleif, W. A., Gabryelski, L. J., Jin, L., Chen, I. W., Ellis, J. D., Mallai, R., and Young, S. D. (2007) Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors, Bioorg. Med. Chem. Lett.17, 5595-5599.

  20. My Current Research Could the FDA-approved anti-HIV drugs be promising anti-cancer agents? An answer from extensive molecular dynamic analyses

  21. Acknowledgement • Dr Mahmoud Soliman(my supervisor) & the lab members • CHPC (Technical support) • UKZN School of health sciences (Financial support)

  22. Thank you

More Related